Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 00:13:25 Source:healthViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Student fatally shot, suspect detained at Georgia's Kennesaw State University
Next:Investigators return to Long Island home of Gilgo Beach serial killing suspect
You may also like
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
- US applications for jobless claims fall to lowest level in 9 weeks
- Rosie Huntington
- Water system from early Shang Dynasty discovered in central China
- Mohammad Mokhber: Who is Iran’s acting president?
- Ship comes under attack off coast of Yemen as Houthi rebel campaign appears to gain new speed
- Not every WNBA draft pick will make her team's roster. Here's why
- Atletico Madrid battles Athletic Bilbao for 4th place in Spain and last Champions League berth
- Amtrak train hits pickup truck in upstate New York, 3 dead including child